Accumulating evidence shows that the downregulation of tumor suppressor genes is achieved through three main mechanisms, including genetic alterations, promoter methylation, or protein instability.[29, 30] To address the underlying mechanism of SCRN2 downregulation in TNBC, we first analyzed genetic alterations of SCRN2 using the cBioPortal for Cancer Genomics (https://www.cbioportal.org).[31] Results showed that the mutation frequency of SCRN2 in all breast cancers and TNBC was lower than 1% (Figure S2A–C, Supporting Information). The gene discussed is SCRN2; the disease is breast carcinoma.